Christine E. Horak

35.7k citations

72 papers · 5.0k indexed · 3 hit papers · h-index 32

Oncology top 0.5%
Molecular Biology top 2%
Immunology top 2%
Pulmonary and Respiratory Medicine top 5%
Cancer Research top 5%

Co-authors: M Snyder David Botstein Vishwanath R. Iyer Charles Scafe Patrick O. Brown Patricia S. Steeg Jeffrey S. Weber Jedd D. Wolchok
Topics: Cancer Immunotherapy and Biomarkers (35 papers)CAR-T cell therapy research (25 papers)Immunotherapy and Immune Responses (15 papers)
Cited by: Oncology Immunology Molecular Biology
Journals: Nature Proceedings of the National Academy of Sciences Nature Genetics
Partner nations: United States France Germany

In The Last Decade

Christine E. Horak

72 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF

2001 841 citations Vishwanath R. Iyer, Christine E. Horak et al. Nature profile →
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

2013 440 citations Jeffrey S. Weber, Christine E. Horak et al. Journal of Clinical Oncology profile →
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

2018 408 citations Scott J. Rodig, Daniel Gusenleitner et al. Science Translational Medicine profile →

Peers

Countries citing papers authored by Christine E. Horak

Since Specialization

Citations

This map shows the geographic impact of Christine E. Horak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine E. Horak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine E. Horak more than expected).

Fields of papers citing papers by Christine E. Horak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine E. Horak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine E. Horak. The network helps show where Christine E. Horak may publish in the future.

Co-authorship network of co-authors of Christine E. Horak

This figure shows the co-authorship network connecting the top 25 collaborators of Christine E. Horak. A scholar is included among the top collaborators of Christine E. Horak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine E. Horak. Christine E. Horak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma 2019 ·Cancer Immunology Research ·Erik Yusko,Marissa Vignali,Richard K. Wilson,Elaine R. Mardis,F. Stephen Hodi,Christine E. Horak,Han Chang,David Woods,Harlan Robins,Jeffrey S. Weber	38
2	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanomabreakdown → 2018 ·Science Translational Medicine ·Scott J. Rodig,Daniel Gusenleitner,Donald Jackson,Evisa Gjini,Anita Giobbie‐Hurder,Chelsea Jin,Han Chang,Scott B. Lovitch,Christine E. Horak,Jeffrey S. Weber,Jason L. Weirather,Jedd D. Wolchok,Michael A. Postow,Anna C. Pavlick,Jason Chesney,F. Stephen Hodi	408
3	Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study 2017 ·Annals of Oncology ·Matthew D. Galsky,Abdel Saci,Péter M. Szabó,Alex Azrilevich,Christine E. Horak,Alexandre Lambert,Arlene O. Siefker‐Radtke,Andrea Necchi,Padmanee Sharma	49
4	Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma. 2017 ·Journal of Clinical Oncology ·Diana Miao,Claire A. Margolis,Dylan J. Martini,Stephanie A. Mullane,Dana Cullen,Christine E. Horak,Megan Wind‐Rotolo,Matthew D. Hellmann,Martin H. Voss,Robert J. Motzer,Craig Norton,Sabina Signoretti,Alexandra Snyder,Eliezer M. Van Allen,Toni K. Choueiri	3
5	PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis 2016 ·Annals of Oncology ·Georgina V. Long,James Larkin,Paolo A. Ascierto,F. Stephen Hodi,Piotr Rutkowski,(unknown),J.C. Hassel,Célèste Lebbé,Anna C. Pavlick,John Wagstaff,Dirk Schadendorf,Reinhard Dummer,David Hogg,J.B.A.G. Haanen,Pippa Corrie,Christoph Höeller,Christine E. Horak,Jedd D. Wolchok,Caroline Robert	18
6	Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab 2016 ·Annals of Oncology ·Jeffrey S. Weber,Christine E. Horak,F. Stephen Hodi,Han Chang,David Woods,Catherine Sanders,Harlan Robins,Erik Yusko	9
7	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? 2016 ·Drugs ·Lucia Festino,Gerardo Botti,Paul Lorigan,Giuseppe Masucci,Jason Hipp,Christine E. Horak,Ignacio Melero,Paolo A. Ascierto	120
8	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). 2015 ·Journal of Clinical Oncology ·Jedd D. Wolchok,Vanna Chiarion‐Sileni,René González,Piotr Rutkowski,Jean‐Jacques Grob,C. Lance Cowey,Christopher D. Lao,Dirk Schadendorf,Pier Francesco Ferrucci,Michael Smylie,Reinhard Dummer,Andrew Hill,John B.A.G. Haanen,Michele Maio,Grant A. McArthur,Arvin Yang,Linda Rollin,Christine E. Horak,James Larkin,F. Stephen Hodi	7
9	CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL) 2015 ·Annals of Oncology ·Jedd D. Wolchok,Vanna Chiarion‐Sileni,René González,Piotr Rutkowski,Jean‐Jacques Grob,C. Lance Cowey,Christopher D. Lao,Dirk Schadendorf,Pier Francesco Ferrucci,Michael Smylie,Reinhard Dummer,Andrew Hill,J.B.A.G. Haanen,Michele Maio,Grant A. McArthur,Allison L. Yang,Lætitia Rollin,Christine E. Horak,James Larkin,F. Stephen Hodi	6
10	Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer 2013 ·Clinical Cancer Research ·Christine E. Horak,Lajos Pusztai,Guan Xing,Ovidiu C. Trifan,Cristina Saura,Ling‐Ming Tseng,Stephen Chan,(unknown),David Liu	83
11	Comparison of KRAS Genotype: Therascreen Assay vs. LNA-Mediated qPCR Clamping Assay 2013 ·Clinical Colorectal Cancer ·(unknown),Jonathan Denne,Luping Zhao,Christine E. Horak,George Green,Shirin Khambata‐Ford,Christopher L. Bray,Ilhan Celik,Eric Van Cutsem,Christopher Harbison	5
12	An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL). 2013 ·Journal of Clinical Oncology ·Jeffrey A. Sosman,Salvador Martín‐Algarra,Jedd D. Wolchok,William H. Sharfman,Shailender Bhatia,F. Stephen Hodi,Wen‐Jen Hwu,Thomas F. Gajewski,Craig L. Slingluff,Howard L. Kaufman,Manish Gupta,(unknown),Christine E. Horak,Christoph M. Ahlers,Jon M. Wigginton,Walter J. Urba	3
13	Effect of Inhibition of the Lysophosphatidic Acid Receptor 1 on Metastasis and Metastatic Dormancy in Breast Cancer 2012 ·JNCI Journal of the National Cancer Institute ·(unknown),Joshua W. Collins,Joji Nakayama,Christine E. Horak,David J. Liewehr,Seth M. Steinberg,(unknown),Fernando Vidal‐Vanaclocha,Diane Palmieri,M. Barbier,Maximilien Murone,Patricia S. Steeg	108
14	Alterations in Gemin5 Expression Contribute to Alternative mRNA Splicing Patterns and Tumor Cell Motility 2008 ·Cancer Research ·Jong‐Heun Lee,Christine E. Horak,Chand Khanna,Zhaojing Meng,Yu Li,Timothy D. Veenstra,Patricia S. Steeg	41
15	Nm23-H1 Suppresses Tumor Cell Motility by Down-regulating the Lysophosphatidic Acid Receptor EDG2 2007 ·Cancer Research ·Christine E. Horak,Jong‐Heun Lee,Abdel Elkahloun,Mathieu Boissan,Sylvie Dumont,Tara Maga,Sandrine Arnaud‐Dabernat,Diane Palmieri,William G. Stetler‐Stevenson,Marie‐Lise Lacombe,Paul S. Meltzer,Patricia S. Steeg	99
16	Nm23-H1 Suppresses Metastasis by Inhibiting Expression of the Lysophosphatidic Acid Receptor EDG2 2007 ·Cancer Research ·Christine E. Horak,Arnulfo Mendoza,Eleazar Vega-Valle,(unknown),Cari Graff‐Cherry,William G. McDermott,Emily Hua,Maria J. Merino,Seth M. Steinberg,Chand Khanna,Patricia S. Steeg	73
17	GATA-1 binding sites mapped in the β-globin locus by using mammalian chIp-chip analysis 2002 ·Proceedings of the National Academy of Sciences ·Christine E. Horak,Milind Mahajan,Nicholas M. Luscombe,Mark Gerstein,Sherman M. Weissman,M Snyder	136
18	ChIP-chip: A genomic approach for identifying transcription factor binding sites 2002 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Christine E. Horak,M Snyder	133
19	Complex transcriptional circuitry at the G1/S transition in Saccharomyces cerevisiae 2002 ·Genes & Development ·Christine E. Horak,Nicholas M. Luscombe,Jiang Qian,Paul Bertone,(unknown),Mark Gerstein,M Snyder	212
20	Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBFbreakdown → 2001 ·Nature ·Vishwanath R. Iyer,Christine E. Horak,Charles Scafe,David Botstein,M Snyder,Patrick O. Brown	841

About Christine E. Horak

Christine E. Horak is a scholar working on Oncology, Cancer Research and Immunology, having authored 72 papers that have together received 5.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (35 papers), CAR-T cell therapy research (25 papers) and Immunotherapy and Immune Responses (15 papers). The work is most often cited by research in Oncology (2.7k citations), Immunology (1.4k citations) and Molecular Biology (2.6k citations). Christine E. Horak has collaborated with scholars based in United States, France and Germany. Frequent co-authors include M Snyder, David Botstein, Vishwanath R. Iyer, Charles Scafe, Patrick O. Brown, Patricia S. Steeg, Jeffrey S. Weber, Jedd D. Wolchok, F. Stephen Hodi and Mark Gerstein. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact